#United States #New York #Gross Law Firm #Cerevel Therapeutics #ABBV

Legal Action Alert: Join the Class Action Suit Against ABBV Before June 3, 2025

Legal Action Notice for Shareholders of Cerevel Therapeutics

On May 1, 2025, The Gross Law Firm announced a critical alert to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV), urging those who purchased shares during a specified period to take action. This announcement serves as a call to arms for investors affected by what the firm describes as a significant market manipulation involving the recent merger of Cerevel and AbbVie Inc.

Overview of the Class Action Suit

This class action lawsuit encompasses all individuals or entities that owned or sold shares of Cerevel from October 11, 2023, up to and including August 1, 2024. It particularly highlights those who held shares as of January 8, 2024, the record date for the merger vote with AbbVie. Under the spotlight are the claims that the merger announcement led to substantial financial repercussions for many investors due to misleading practices surrounding the merger.

The core allegations claim that during the October 16, 2023, secondary offering of Cerevel’s stock, critical information regarding AbbVie’s acquisition interest was omitted. This resulted in Cerevel’s stock price being artificially lowered to $22.81 per share, a price that diverged significantly from AbbVie’s eventual acquisition offer of $45 per share. Allegations have arisen that key players, including Bain Capital, possessed insider knowledge about AbbVie's plans, allowing them to purchase shares at profoundly depressed prices.

The Importance of Action

Shareholders are reminded that the deadline to register for the class action is June 3, 2025. Investors interested in joining the suit are encouraged to register promptly, as failing to do so may result in the loss of eligibility to recover any potential losses related to the allegations.

Benefits of joining the class action include receiving updates and monitoring of case developments. Importantly, registering as a lead plaintiff is not mandatory for participation in the recovery process. The Gross Law Firm emphasizes that no fees are incurred when registering for this action.

Why Choose The Gross Law Firm?

Renowned for their commitment to safeguarding investor rights, The Gross Law Firm has built a reputation as a prominent force in class action litigation. They seek to hold corporations accountable for deceptive practices and ensure fair treatment for all investors. Their mission aims to counteract corporate malpractice and provide a path toward financial restitution for those who have experienced losses due to misrepresentation or illegal actions.

Shareholders concerned about their investments in Cerevel Therapeutics are therefore encouraged to take proactive measures by contacting The Gross Law Firm for advice or registration. For further details, they can visit the designated webpage for registration and outline specifics regarding the nature of the claims.

In summary, this class action suit stands as a significant opportunity for affected shareholders to seek justice and recover their investments leading into the forthcoming legal proceedings.

For inquiries and further assistance, interested shareholders can reach The Gross Law Firm at: